← back to the index
DV-014 venous thromboembolism 2015

The Bard Recovery IVC Filter — Struts That Broke Loose and Killed 27

concealmentdeathmechanical-fracturemigration-embolizationinterventional-radiologyvascular-medicine2000s2010s
Patients implanted
~34,000 Recovery (+~160,000 G2-series)
Failure or harm
≥27 deaths, 300+ adverse events (NBC); fracture/migration far above competitors
In use
~2.5 yrs (Recovery, mid-2003 – 2005 before replacement)
Status
Withdrawn

Summary

When C.R. Bard stopped selling its Recovery inferior vena cava filter in 2005, it did not recall the device or warn the roughly 34,000 patients carrying one inside the largest vein in the body; it replaced the Recovery with a cosmetically modified successor, the G2, and the gap between the promise and the harm was by then already documented in Bard's own files. The Recovery was marketed as the first retrievable IVC filter cleared in the United States — a spider-shaped nitinol cage meant to catch blood clots traveling toward the heart and lungs and then, unlike permanent filters, to be removed once the danger passed. A confidential study Bard commissioned in 2004 found the opposite of a safe device: the Recovery carried higher relative risk of death, filter fracture, and migration than every competing filter on the market.

The failure mechanism was mechanical and lethal. The Recovery's thin struts fractured, and the broken fragments — sharp lengths of nitinol — embolized through the bloodstream into the right heart and the pulmonary arteries, or the whole filter migrated and perforated the vena cava wall. A December 2005 internal Bard document, later obtained by NBC News, recorded that the Recovery had an "11.5 times higher reporting rate for filter embolization deaths" than all other vena cava filters combined. Bard had recruited a veteran regulatory specialist, Kay Fuller, to shepherd the FDA clearance; Fuller refused to sign the application over safety concerns, and the application reached the FDA bearing what she says is a forged version of her signature.

Rather than recall the Recovery after the 2004 report urged urgent investigation, Bard withdrew it from sale in 2005 and sold the G2 — a device Bard's own records show it knew was fracturing and migrating within four months of clearance. The death toll surfaced not through a regulator but through a year-long NBC News investigation broadcast in September 2015, which linked the Recovery to at least 27 deaths and more than 300 non-fatal injuries. Thousands of suits consolidated into a multidistrict litigation in Arizona, and the first bellwether — Sherr-Una Booker, whose G2 fractured and required open-heart surgery — produced a $3.6 million verdict in March 2018, including $2 million in punitive damages. The FDA never recalled the Recovery; the legend of the "retrievable" filter ended as a case study in replacing a known-defective implant instead of retrieving it.

Timeline

2002
Bard recruits a regulatory specialist
Bard hires veteran regulatory consultant Kay Fuller to help win FDA clearance for the Recovery; she declines to sign the application over unresolved safety concerns.
Jul 2003
First retrievable clearance
The FDA clears the Recovery via the 510(k) pathway — no human clinical trials required — as the first IVC filter in the U.S. marketed as retrievable.
2003–2005
Reports of fracture and migration accumulate
Adverse-event reports of struts breaking and fragments embolizing to the heart and lungs begin to mount during the Recovery's brief time on the market.
2004
The confidential study
A study Bard commissions (led by consultant Dr. John Lehmann) finds the Recovery has higher relative risk of death, fracture, and migration than competing filters and urges further investigation.
2005
Withdrawal without recall
Bard stops selling the Recovery and replaces it with the modified G2 — but issues no recall and does not retrieve devices already implanted.
~2005
G2 fails early too
Internal Bard records note the G2 is fracturing and migrating within roughly four months of its own FDA clearance.
Dec 2005
The 11.5x memo
An internal Bard document records that the Recovery had an "11.5 times higher reporting rate for filter embolization deaths" than all other vena cava filters.
Jun 2007
A representative injury
Sherr-Una Booker is implanted with a Bard G2; it later fractures and migrates, requiring open-heart surgery, with a fragment left lodged in her vena cava wall.
Aug 2010
FDA safety communication
The FDA reports 921 IVC-filter adverse-event notifications over five years — 328 migrations, 146 embolizations, 70 perforations, 56 fractures — and urges removal once protection is no longer needed.
May 7, 2014
FDA updates guidance
A second FDA safety communication recommends retrievable filters be removed roughly 29–54 days after implantation once the transient clot risk has passed.
Sep 2015
NBC exposé
A year-long NBC News investigation links the Recovery to ≥27 deaths and 300+ injuries and reveals the forged-signature and replace-not-recall record.
Mar 30, 2018
First bellwether verdict
A Phoenix federal jury in MDL 2641 awards Booker $3.6 million — $1.6 million compensatory plus $2 million punitive — finding Bard failed to warn of elevated fracture and migration.

The First "Retrievable" Filter and the Signature Nobody Would Sign

The Recovery's selling proposition was retrievability. Permanent IVC filters had existed for decades as a fallback for patients who could not take anticoagulants, but they stayed in the body forever, accumulating long-term risk. Bard's Recovery — a cone of fine nitinol struts with hooked legs to anchor in the vena cava and curved arms to catch clots — was the first cleared in the United States to be marketed as removable once the danger of pulmonary embolism passed. That clearance came in July 2003 through the FDA's 510(k) program, which permits a device to reach patients by demonstrating "substantial equivalence" to an existing product rather than by passing human clinical trials. The device that would fracture inside tens of thousands of people was never required to prove itself in a trial. Bard's own regulatory specialist, Kay Fuller, recruited to push the application through, refused to sign it because her safety concerns were unresolved — and the application reached the agency anyway, bearing what she has testified is not her signature. The wonder of a retrievable filter, like the wonder of so many withdrawn devices, was certified by a process built to move fast, not to look hard.

The Struts That Broke and the Study That Was Buried

The defect was structural and it was understood early. The Recovery's thin nitinol legs fractured under the constant flexing of a beating circulatory system, and the consequences of a fracture were catastrophic by design: a broken strut is a free metal splinter inside the largest vein returning blood to the heart, and the bloodstream carries it directly to the right ventricle and the pulmonary arteries. Whole filters migrated and tilted, their hooks perforating the vena cava wall. In 2004 — within roughly a year of launch — Bard commissioned its own study, led by consultant Dr. John Lehmann, which found that the Recovery carried higher relative risk of death, fracture, and migration than every competitor and recommended urgent further study. By December 2005 an internal document put a number on it: an embolization-death reporting rate 11.5 times higher than all other vena cava filters combined. The signal was not missing. It existed inside Bard, in writing, before most of the harm was litigated — and it did not become a recall, a warning to physicians, or a notice to patients.

Replace, Don't Recall, and the Reckoning Television Forced

What Bard did with that signal defines the case. Instead of recalling the Recovery and retrieving or warning about devices already implanted, the company stopped selling it in 2005 and substituted the G2 — a device Bard's own records show was fracturing and migrating within about four months of its clearance. Withdrawal replaced recall; a new product number replaced an admission. No FDA recall of the Recovery ever issued. The death toll became public only because a journalist counted it: NBC News spent roughly a year assembling adverse-event data and internal documents, and its September 2015 broadcast tied the Recovery to at least 27 deaths and more than 300 injuries, aired Kay Fuller's forged-signature account, and showed Bard had known its replacement was failing too. Litigation, not regulation, then did the accounting. Thousands of suits consolidated into MDL 2641 in Arizona, and in March 2018 the first bellwether jury awarded Sherr-Una Booker $3.6 million — $2 million of it punitive — for Bard's failure to warn physicians of fracture and migration rates it had measured years earlier. The device had been off the market for thirteen years before a jury read the files.

Contributing Factors

01
A clearance pathway without clinical trials
The Recovery reached patients through the FDA's 510(k) "substantial equivalence" route, which requires no human trial of the new device. A novel retrievable implant whose central failure mode — strut fracture under cyclic loading — could only be found in vivo was cleared on a paper comparison, so the trial that would have exposed the defect happened inside 34,000 patients.
02
A known defect documented and not acted on
Bard's own 2004 commissioned study found elevated death, fracture, and migration risk versus competitors, and a December 2005 memo recorded an 11.5x embolization-death reporting rate. The lethal mechanism was quantified internally before most of the harm and litigation; the failure was suppression of a measured signal, not ignorance of it.
03
Withdrawal as a substitute for recall
Bard removed the Recovery from sale in 2005 but issued no recall, retrieved nothing, and warned no one — then sold the G2 in its place. Treating a new product line as the remedy for a defective implant left tens of thousands of filters fracturing inside patients who were never told, converting a manufacturing decision into an open-ended in-body hazard.
04
A successor that inherited the defect
The G2 was marketed as an improvement, yet Bard's records show it fractured and migrated within roughly four months of its own clearance. Replacing a defective device with a cosmetically modified version that shares the failure mode multiplies exposure while preserving the appearance of correction — the harm scaled to ~160,000 additional filters.
05
Journalism and litigation as the only working regulator
No FDA recall forced the reckoning; an NBC News investigation surfaced the death count and the forged signature, and MDL discovery surfaced the memos. When the regulatory pathway that cleared a device cannot revisit it, the death toll is tallied by reporters and the liability fixed by juries, years after the device is gone.

Aftermath

The Recovery's most durable consequence was to harden the public and legal record on retrievable IVC filters as a class. NBC's 2015 investigation drove patient awareness and fed a litigation wave; MDL 2641 in Arizona consolidated thousands of claims, and after the $3.6 million Booker verdict in 2018 Bard resolved the bulk of the inventory through settlements. The FDA, which never recalled the Recovery, had already shifted its posture with the 2010 and 2014 safety communications urging that retrievable filters be removed promptly — between 29 and 54 days once the clot risk passes — an implicit concession that filters left in place were a hazard the original "retrievable" marketing had obscured. Clinically, retrieval rates and the threshold for implanting a filter at all came under sustained scrutiny. The Recovery is now the standard cautionary citation for the "replace, don't recall" maneuver: the case invoked whenever a manufacturer answers an internal safety study by quietly substituting a near-identical successor and leaving the defective device inside the patients who already have it.

Lessons

  1. Treat a clearance that skips human trials as an unfinished safety question, not a verdict — if a device's principal failure mode can only appear in the body, assume the post-market population is the trial and surveil it as one.
  2. When your own commissioned study finds elevated death, fracture, or migration risk, the only defensible response is to warn and to recall; a confidential report urging investigation that is answered by a new product number is the single most damaging document discovery will surface.
  3. Distinguish withdrawal from recall absolutely: pulling a device from sale does nothing for the implants already inside patients, so make retrieval-or-warning of the deployed hazard the obligation, never cessation of new sales.
  4. A successor device must clear the defect, not the optics — replacing a failing implant with a cosmetically modified version that shares the failure mode multiplies the body count and compounds the liability.
  5. Assume the death toll you do not publish will be published for you — write every internal memo expecting a reporter and a jury to read it, because in mass-harm device cases both will.

References